People with Barrett's esophagus are at higher than average risk of developing esophageal cancer. Obeticholic Acid (OCA) is a medication similar to bile acids (a fluid made and released by the liver). OCA binds to a group of cells in the intestine that is believed to have a positive effect on preventing cancer development. The purpose of this study is to compare the safety and effects of OCA with that of a placebo on the risk of developing esophageal cancer in people with Barrett's esophagus.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Nicholas Shaheen
Medicine-Gastroenterology
Clinical or Medical
Interventional
Stomach, Digestion and Gut Health
22-3141
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
